HIV Prevention Tx May Also Prevent Genital Herpes
the MPR take:
Daily oral preexposure of the antiretroviral tenofovir disoproxil fumarate (TDF) (Viread; alone or in combination with emtricitabine (FTC–TDF) can reduce the risk of sexually acquired HIV, but can it also lower the risk of acquiring herpes simplex virus type 2 (HSV-2)? In an Annals of Internal Medicine study, 131 HIV and HSV-2 negative heterosexual men and women at high risk for HIV infection (due to having an HIV-infected partner) were assigned to tenofovir or FTC–TDF PrEP, or placebo. Among the participants with HSV-2 infected partners the hazard ratio for PrEP was 0.67 (CI, 0.46–0.98; P=0.038) vs. placebo and the absolute risk reduction was 3.1 per 100 person-years. This modest protection against HSV-2 infection is an added benefit of HIV prevention with an oral tenofovir-based PrEP, the researchers concluded.
Background: Daily oral preexposure prophylaxis (PrEP) using the antiretroviral tenofovir disoproxil fumarate (TDF) alone or in combination with emtricitabine (FTC-TDF) reduces the risk for HIV-1 acquisition. Tenofovir has in vitro activity against herpes simplex virus type 2 (HSV-2). (ClinicalTrials.gov: NCT00557245) Setting:Multiple sites in Kenya and Uganda.
READ FULL ARTICLE From Annals